OMER - Omeros announces data for narsoplimab in pivotal trial for rare disease linked to stem cell transplantation

Omeros Corporation (OMER) released the results on organ function improvement for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).Narsoplimab, (OMS721) is an investigational human monoclonal antibody targeting an enzyme called MASP-2 for which Omeros controls worldwide rights.In the study, 61% of the intent-to-treat ((ITT)) population (any patient receiving at least 1 dose of narsoplimab) and 74% of the per-protocol ((PP)) population (those patients receiving ? 4 weeks of dosing) responded to the treatment, according to the company.There was organ function improvement of 74% and 77% of eligible patients in the ITT and PP groups, Omeros said referring to 67%, 50%, and 100% in kidney, neurologic, or gastrointestinal function, respectively.48% and 55% of patients in the ITT and PP groups experienced freedom from transfusion, respectively. There were six deaths during the core study period due to causes common in HSCT. However, the experimental therapy was well tolerated with no

For further details see:

Omeros announces data for narsoplimab in pivotal trial for rare disease linked to stem cell transplantation